Imagine trying to protect a house from intruders, but the front door is a slippery mucosal surface where most medicines just wash away. This project creates a special 'sticky' delivery system, like a thin film you put in your mouth, to train the immune system right where the bacteria attack. By using H. pylori as a test case, they are building a blueprint to stop gut-based infections that are becoming resistant to antibiotics.
Traditional vaccines often fail to trigger immunity in the gastrointestinal tract, leaving 50% of the global population vulnerable to H. pylori and subsequent gastric cancer, especially as antimicrobial resistance grows.
A subunit fusion vaccine with two antigens and a ready-to-use adjuvant for bed-side-mix, delivered via an innovative oro-mucosal film.
If you are a vaccine developer dealing with the failure of traditional injections to protect the gut — this project developed a subunit fusion vaccine and oro-mucosal film that induces strong mucosal immune responses. This allows for a 'systemic prime and mucosal pull' strategy to ensure long-term protection.
If you are a drug delivery specialist dealing with the difficulty of administering medicine to the GI tract — this project developed a ready-to-use adjuvant for bed-side-mix. This technology can be adapted for various AMR mucosal pathogens to reduce disease burden.
If you are a clinic network dealing with the high risk of gastric cancer from H. pylori infections affecting 50% of the global population — this project developed a prophylactic lead candidate. This provides a preventative tool to stop the progression of chronic bacterial infections into cancer.
Based on available project data, no specific pricing or cost-per-dose information is provided.
The project has already advanced GMP manufacturing for a subunit fusion vaccine, indicating a path toward industrial-scale production.
Based on available project data, specific licensing terms are not listed, but the project delivers a ready-to-use adjuvant and vaccine technologies for translation into clinical pipelines.
The project is moving toward a clinical phase I study to evaluate immunogenicity and safety, which is a critical step in the regulatory approval process.
It acts as a prophylactic alternative to antibiotics, aiming to reduce the reliance on antimicrobial treatments for GI pathogens.
The consortium is well-balanced for translation, consisting of 10 partners across 8 countries. With a 20% industry ratio (2 companies, including 2 SMEs) and 5 universities, the project blends academic research with commercial manufacturing capabilities, specifically in GMP production.
Contact the Technical University of Munich (TUM) regarding the mucosal vaccine platform.
Contact SciTransfer to explore licensing opportunities for the oro-mucosal film technology.
